• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Scynexis Inc (NQ: SCYX )

    1.330 +0.010 (+0.76%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Scynexis Inc

    < Previous 1 2 3 4 Next >
    SCYX Stock Earnings: SCYNEXIS Misses EPS, Misses Revenue for Q2 2024
    SCYX stock results show that SCYNEXIS missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
    Via InvestorPlace
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    Pre-market stock movers are a hot topic that traders are going to want to know about and we have all of the latest news on Tuesday morning! 
    Via InvestorPlace
    3 Stocks Under $10 With the Potential for Massive Gains
    Discover the growth potential of top small-cap stocks in the consumer finance, healthcare equipment and pharmaceutical industries. 
    Via InvestorPlace
    3 Dirt-Cheap Drug Developers With Blockbuster Potential
    These are three of the best cheap drug developer stocks for investors to keep an eye as their growth could be imminent. 
    Via InvestorPlace
    7 Undervalued Biotech Stocks to Buy for Big-Time Returns
    The broader healthcare sector enjoys a powerfully relevant narrative. Undervalued biotech stocks makes the case even more attractive. 
    Via InvestorPlace
    Should you consider SCYNEXIS INC (NASDAQ:SCYX) for growth investing?
    Exploring SCYNEXIS INC (NASDAQ:SCYX)'s growth characteristics. 
    Via Chartmill
    SCYNEXIS: Q1 Earnings Insights
    Via Benzinga
    Looking Into SCYNEXIS's Return On Capital Employed
    Via Benzinga
    Hidden Gems: 3 Under-$10 Stocks Poised for 500% Growth by 2025
    Read here about the top under-$10 growth stocks primed for financial success through strategic partnerships and innovative product offerings. 
    Via InvestorPlace
    3 Stocks Under $10 With Mammoth Growth Prospects
    Learn more about the growth stocks under $10 with progressive fundamentals in the healthcare and technology sectors. 
    Via InvestorPlace
    SCYX Stock Earnings: SCYNEXIS Beats EPS, Misses Revenue for Q1 2024
    SCYX stock results show that SCYNEXIS beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
    Via InvestorPlace
    SCYX Stock Earnings: SCYNEXIS Misses EPS, Beats Revenue for Q4 2023
    SCYX stock results show that SCYNEXIS missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
    Via InvestorPlace
    5 Value Stocks To Watch In The Healthcare Sector
    Via Benzinga
    A Look Into Healthcare Sector Value Stocks
    Via Benzinga
    Why Resources Connection Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
    Shares of Resources Connection, Inc. (NASDAQ: RGP) rose sharply in pre-market trading following better-than-expected results for its second quarter. 
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    Gold Moves Lower; TransCode Therapeutics Shares Surge
    U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite trading higher by around 30 points on Monday. The Dow traded down 0.07% to 33,939.93 while the NASDAQ rose 0.24% to... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Why Brainstorm Cell Therapeutics Shares Are Trading Lower By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138. 
    Via Benzinga
    Nasdaq Turns Higher; SCYNEXIS Shares Plunge
    U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite trading higher on Monday. The Dow traded down 0.01% to 33,962.53 while the NASDAQ rose 0.26% to 13,246.15. The S&P 500... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Are Antifungal Focused Scynexis Stock Plunging Today?
    Scynexis Inc (NASDAQ: SCYX) is voluntarily recalling its antifunga 
    Via Benzinga
    U.S. Stocks Open Lower; Chicago Fed Index Falls In August
    U.S. stocks traded mostly lower this morning, with the Dow Jones trading falling around 80 points on Monday. Following the market opening Monday, the Dow traded down 0.26% to 33,875.83 while the NASDAQ... 
    Via Benzinga
    Topics Economy Stocks
    Exposures Interest Rates US Equities
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Want to Get Rich? 3 Game-Changing Penny Stocks to Buy Right Now
    While the very concept of penny stocks to buy is treacherous, these analyst-backed ideas could be enticing for the smart speculator. 
    Via InvestorPlace
    Why DLocal Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket
    Gainers 
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Dow Rises 100 Points; Accelerate Diagnostics Shares Spike Higher
    U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 100 points on Thursday. The Dow traded up 0.31% to 32,819.16 while the NASDAQ rose 0.63% to 12,001.83. The S&P... 
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Why Bed Bath & Beyond Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Gainers SCYNEXIS, Inc. (NASDAQ: SCYX) shares climbed 68% to $2.8184 after the company announced an exclusive license agreement with GSK for Brexafemme, in which the company will receive an upfront... 
    Via Benzinga
    < Previous 1 2 3 4 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.